Skip to content
MamaGLP — home

Evidence review

Is a GLP-1 right for me? A gentle explainer for moms

Who may be considered for a GLP-1, which health and pregnancy questions matter, and what to ask before agreeing to treatment or payment.

Written by Camila Rael, editora mom, not a clinician treating youPublished Updated

Our medical guides link to published research and official medication information. Provider reviews compare published costs and terms. These source checks do not replace clinical review or advice from your healthcare professional.

A conversation does not commit you to treatment

You can ask about medication without having decided to take it. The appointment should help you understand the health problem being treated, the available options and what follow-up would involve. You do not need to describe yourself as a failure or prove that you have tried hard enough to deserve a careful discussion.

A website can explain questions and published terms. It cannot assess your symptoms, confirm a diagnosis or decide which prescription is appropriate. If the names are unfamiliar, GLP-1 basics is a useful starting point before discussing an actual product.

Who may be considered for weight-management medication

For adults, NIDDK describes consideration of prescription weight-management medication at a BMI of 30 or above, or 27 or above with a weight-related health problem. It also emphasizes that medication is not appropriate for everyone meeting those figures.1 BMI is one part of an assessment, not an online approval code.

The current Wegovy and Zepbound labels include weight reduction and long-term maintenance for adults with obesity, or overweight with at least one weight-related condition, alongside diet and activity measures.2,3 Other approved uses are product-specific; having an interest in a GLP-1 does not establish that any brand, formulation or indication fits.

Bring diagnoses, blood-pressure or glucose records already collected under your care plan, and the treatments you have tried. A stalled scale, PCOS, insulin resistance or changes after childbirth can be reasons to ask questions, but none automatically establishes eligibility for a particular drug. Ask what the proposed treatment is intended to improve and how that outcome would be measured.

History that can change the recommendation

Both labels list personal or family history of medullary thyroid carcinoma and MEN 2 among contraindications, together with specified allergies to the medicine or ingredients. They also include warnings requiring clinical consideration, such as pancreatitis, gallbladder problems, dehydration-related kidney injury and glucose lowering with certain diabetes medicines. Both are not recommended in severe gastroparesis.2,3 A warning and a contraindication are different; disclose the history rather than deciding from a checklist that every past digestive problem is an absolute exclusion.

Bring a complete medicine and supplement list, including another GLP-1, insulin or other diabetes treatment. Do not stop existing prescriptions to make yourself seem a better candidate. Tell the clinician about current eating difficulties, previous treatment reactions and any planned anesthesia or deep sedation. If treatment is proposed, ask who will respond to new symptoms and coordinate with your existing care team.

Pregnancy, contraception and nursing need a plan

For weight management, these medicines are not a pregnancy treatment. The labels direct discontinuation when pregnancy is recognized, and pregnancy planning needs discussion before starting.2,3 Our trying-to-conceive guide helps organize the timing questions; it does not replace instructions from the prescriber.

Tirzepatide has a specific oral hormonal contraceptive interaction: the Zepbound label advises a non-oral method or added barrier protection for four weeks after starting and four weeks after each dose increase.3 If this applies to you, discuss the contraception plan before the first dose.

Breastfeeding requires a product-specific conversation. The Wegovy label does not recommend breastfeeding during tablet treatment; do not transfer advice about one formulation to every other product.2 Use the breastfeeding evidence guide to prepare questions about your infant, treatment need and alternatives.

Clinical suitability and affordability are separate decisions

Ask what the initial visit costs, whether medication and required tests are included, what you owe if no prescription is issued, and how continuing care is billed. A refund promise or low introductory price cannot establish that a medicine suits you. The uninsured cost guide explains those payment units without promising coverage or a particular quote.

If a compound is proposed, ask why that exact formulation is needed rather than assuming it is an approved generic. You can request time to read a written plan, compare alternatives or seek another opinion. A useful first appointment can end with medication, further assessment or a decision to wait; the important outcome is understanding the reason and the next step.

Frequently asked questions

Does meeting a BMI threshold mean I will receive a prescription?

No. BMI can help identify when assessment is appropriate, but the clinician must consider the actual indication, history, other medicines, risks and treatment goals.

Does PCOS or insulin resistance automatically make me a candidate?

No. Those concerns may be relevant to a consultation, but they do not by themselves establish eligibility for every GLP-1 medicine or formulation.

What should I bring to the appointment?

Bring diagnoses, relevant records already available, a complete medicine and supplement list, previous treatment reactions, pregnancy or nursing plans, and questions about follow-up and full payment terms.

Can a provider ranking decide the right treatment?

No. A comparison can help you examine published services and terms. Clinical suitability requires an assessment by a licensed clinician; a low price or refund policy cannot replace it.

Where this leaves you

References

  1. National Institute of Diabetes and Digestive and Kidney Diseases (2024). Prescription medications to treat overweight and obesity: who might benefit. NIDDK. https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity
  2. Novo Nordisk (2026). Wegovy prescribing information and Instructions for Use: presentation-specific training, administration and precautions. FDA-approved prescribing information. https://www.novo-pi.com/wegovy.pdf
  3. Eli Lilly and Company (2026). Zepbound prescribing information and Instructions for Use, revised August 2026. FDA-approved prescribing information. https://pi.lilly.com/us/zepbound-uspi.pdf

Friendly information, not a prescription. Everything on MamaGLP is here to help you understand your options and ask better questions — it is not a diagnosis, not a treatment plan, and not a nudge to start or stop anything. Only a licensed healthcare professional who knows your history and your goals can tell you what is right for you, so please talk with one before acting on a single word of this.

Keep reading